Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | TLR2 | O60603 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13360295 | 0.89 | MEN1 (0.49) | MEN1KMT2ACA2TLR2 | |
| SCHEMBL13360298 | 0.83 | MEN1 (0.54) | MEN1KMT2ACA2TLR2 | |
| SCHEMBL13328241 | 0.81 | MEN1 (0.53) | MEN1KMT2ACA2TLR2 | |
| SCHEMBL21105932 | 0.81 | KMT2A (0.59) | MEN1KMT2ACA2 | |
| SCHEMBL21105478 | 0.81 | KMT2A (0.59) | MEN1KMT2ACA2 | |
| SCHEMBL22837635 | 0.81 | KMT2A (0.59) | MEN1KMT2ACA2 | |
| SCHEMBL25546667 | 0.81 | KMT2A (0.59) | MEN1KMT2ACA2 | |
| SCHEMBL24812863 | 0.77 | KMT2A (0.53) | MEN1KMT2A | |
| SCHEMBL23945364 | 0.77 | MEN1 (0.46) | MEN1KMT2A | |
| SCHEMBL23696138 | 0.77 | MEN1 (0.46) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210346509-A1 | GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof | ASTRAZENECA AB (SE) | 2021-11-11 | — | — | US | disclosed |
| US-20200268898-A1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. | 2020-08-27 | — | — | US | disclosed |
| US-20190134214-A1 | GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof | ASTRAZENECA AB (SE) | 2019-05-09 | — | — | US | disclosed |
| US-7713944-B2 | Oligomers comprising activated disulfides which bind to plasma proteins and their use for delivery to cells | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190134214-A1 | GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof | GLP1R, GIPR, GRPR | MEN1 1057/4885KMT2A 2228/4885CA2 2800/4885 |
| US-20210346509-A1 | GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof | GLP1R, GIPR, GRPR | MEN1 1057/4885KMT2A 2228/4885CA2 2800/4885 |
| US-20200268898-A1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | GLP1R, GIPR, GRPR | MEN1 1057/4885KMT2A 2228/4885CA2 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.